Castle Biosciences, Inc.CSTLNASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +39.50% | +30.54% | +20.57% | -0.94% | -3.19% |
| Gross Profit Growth | +39.86% | +30.60% | +21.20% | -5.41% | -8.31% |
| EBITDA Growth | +0.00% | +1906.57% | +305.78% | -71.38% | -56.38% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | -184.82% | -233.96% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -49.29% | -122.08% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -50.00% | -121.10% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -51.61% | -125.91% |
| Weighted Average Shares Growth | +3.75% | +3.62% | +4.09% | +4.59% | -10.02% |
| Weighted Average Shares Diluted Growth | +9.57% | +11.26% | +4.09% | +2.81% | -1.12% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +365.64% | +31.09% | +0.00% | -13.24% | -3.03% |
| Free Cash Flow Growth | +563.28% | +13.55% | +0.00% | -38.42% | -54.03% |
| Receivables Growth | +35.83% | +33.72% | +31.98% | +13.75% | -1.55% |
| Inventory Growth | +13.92% | +2.43% | -10.41% | +4.41% | +31.62% |
| Asset Growth | +18.01% | +17.18% | +9.42% | +11.78% | +9.37% |
| Book Value per Share Growth | +10.20% | +12.43% | +5.10% | +2.72% | +17.69% |
| Debt Growth | +84.08% | +71.79% | +3.16% | +48.28% | +38.89% |
| R&D Expense Growth | -4.64% | -10.14% | -8.84% | -9.54% | +5.17% |
| SG&A Expenses Growth | +13.18% | +13.33% | +20.88% | +13.66% | +10.71% |